“The Phase 1 clinical trial is designed to evaluate the safety, reactogenicity, and immunogenicity of ARCT-2304 as a potential vaccine to protect against the highly pathogenic H5N1 avian influenza.” ...
The specimen was collected on Nov. 7, 2024 and DOH received the result on Nov. 12. The type of H5 avian influenza was H5N1, also called Highly Pathogenic Avian Influenza (HPAI). An investigation was ...